Literature DB >> 31729474

PD-1 inhibition enters the frontline.

David Killock1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31729474     DOI： 10.1038/s41571-019-0303-4

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Authors:  Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin
Journal:  Lancet       Date:  2019-11-01       Impact factor: 79.321
  1 in total
  1 in total

1.  Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.

Authors:  Guosheng Yuan; Fuli Xie; Yangda Song; Qi Li; Rong Li; Xiaoyun Hu; Mengya Zang; Xiao Cheng; Guanting Lu; Jing Huang; Wenzhe Fan; Xiaoxiang Rong; Jian Sun; Jinzhang Chen
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.